Susquehanna International Group
SGTX

Susquehanna International Group’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Susquehanna International Group’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,000
Closed -$293K – 13503
2023
Q2 		$293K Buy
13,000
+11,731
+924% +$85.1K ﹤0.01% 9490
2023
Q1 		$15.3K Buy
+1,269
New +$13.2K ﹤0.01% 12114
2022
Q2 		– Sell
-2,308
Closed -$44K – 14374
2022
Q1 		$44K Sell
2,308
-7
-0.3% -$156 ﹤0.01% 12365
2021
Q4 		$83K Buy
+2,315
New +$132K ﹤0.01% 12266

Other funds holding SGTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's SGTX Position: Q2 2023 in Review

Susquehanna International Group sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 11,031 shares — an estimated $80.1K sold.

Susquehanna International Group first reported a position in SGTX in Q3 2021 and held it in 7 quarters. The position peaked at $137K in Q3 2021. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

  • Susquehanna International Group reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 11,031 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $80.1K.
  • Susquehanna International Group first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • Susquehanna International Group's Sigilon Therapeutics, Inc. Common Stock position peaked at $137K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.